Literature DB >> 27721165

Explicit macroscopic singlet oxygen modeling for benzoporphyrin derivative monoacid ring A (BPD)-mediated photodynamic therapy.

Michele M Kim1, Rozhin Penjweini2, Xing Liang2, Timothy C Zhu3.   

Abstract

Photodynamic therapy (PDT) is an effective non-ionizing treatment modality that is currently being used for various malignant and non-malignant diseases. In type II PDT with photosensitizers such as benzoporphyrin monoacid ring A (BPD), cell death is based on the creation of singlet oxygen (1O2). With a previously proposed empirical five-parameter macroscopic model, the threshold dose of singlet oxygen ([1O2]rx,sh]) to cause tissue necrosis in tumors treated with PDT was determined along with a range of the magnitude of the relevant photochemical parameters: the photochemical oxygen consumption rate per light fluence rate and photosensitizer concentration (ξ), the probability ratio of 1O2 to react with ground state photosensitizer compared to a cellular target (σ), the ratio of the monomolecular decay rate of the triplet state photosensitizer (β), the low photosensitizer concentration correction factor (δ), and the macroscopic maximum oxygen supply rate (g). Mice bearing radiation-induced fibrosarcoma (RIF) tumors were treated interstitially with a linear light source at 690nm with total energy released per unit length of 22.5-135J/cm and source power per unit length of 12-150mW/cm to induce different radii of necrosis. A fitting algorithm was developed to determine the photochemical parameters by minimizing the error function involving the range between the calculated reacted singlet oxygen ([1O2]rx) at necrosis radius and the [1O2]rx,sh. [1O2]rx was calculated based on explicit dosimetry of the light fluence distribution, the tissue optical properties, and the BPD concentration. The initial ground state oxygen concentration ([3O2]0) was set to be 40μM in this study. The photochemical parameters were found to be ξ=(55±40)×10-3cm2mW-1s-1, σ=(1.8±3)×10-5μM-1, and g=1.7±0.7μMs-1. We have taken the literature values for δ=33μM, and β=11.9μM. [1O2]rx has shown promise to be a more effective dosimetry quantity for predicting necrosis than either light dose or PDT dose, where the latter is simplistically a temporal integral of the products of the photosensitizer concentration and light fluence rate.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Benzoporphyrin derivative monoacid ring A (BPD); Explicit dosimetry; In vivo mouse study; Photodynamic therapy; Singlet oxygen

Mesh:

Substances:

Year:  2016        PMID: 27721165      PMCID: PMC5079817          DOI: 10.1016/j.jphotobiol.2016.09.031

Source DB:  PubMed          Journal:  J Photochem Photobiol B        ISSN: 1011-1344            Impact factor:   6.252


  36 in total

1.  A method for determination of the absorption and scattering properties interstitially in turbid media.

Authors:  Andreea Dimofte; Jarod C Finlay; Timothy C Zhu
Journal:  Phys Med Biol       Date:  2005-05-05       Impact factor: 3.609

2.  Porphyrin bleaching and PDT-induced spectral changes are irradiance dependent in ALA-sensitized normal rat skin in vivo.

Authors:  J C Finlay; D L Conover; E L Hull; T H Foster
Journal:  Photochem Photobiol       Date:  2001-01       Impact factor: 3.421

3.  Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1999-10

4.  Direct near-infrared luminescence detection of singlet oxygen generated by photodynamic therapy in cells in vitro and tissues in vivo.

Authors:  Mark Niedre; Michael S Patterson; Brian C Wilson
Journal:  Photochem Photobiol       Date:  2002-04       Impact factor: 3.421

5.  Spatial heterogeneity and temporal kinetics of photosensitizer (AlPcS2) concentration in murine tumors RIF-1 and MTG-B.

Authors:  Claudia C Lee; Brian W Pogue; Julia A O'Hara; Carmen M Wilmot; Rendy R Strawbridge; Gregory C Burke; P Jack Hoopes
Journal:  Photochem Photobiol Sci       Date:  2003-02       Impact factor: 3.982

6.  Determination of the distribution of light, optical properties, drug concentration, and tissue oxygenation in-vivo in human prostate during motexafin lutetium-mediated photodynamic therapy.

Authors:  Timothy C Zhu; Jarod C Finlay; Stephen M Hahn
Journal:  J Photochem Photobiol B       Date:  2004-12-02       Impact factor: 6.252

7.  Treatment-induced changes in tumor oxygenation predict photodynamic therapy outcome.

Authors:  Hsing-Wen Wang; Mary E Putt; Michael J Emanuele; Daniel B Shin; Eli Glatstein; Arjun G Yodh; Theresa M Busch
Journal:  Cancer Res       Date:  2004-10-15       Impact factor: 12.701

8.  Hypoxia and Photofrin uptake in the intraperitoneal carcinomatosis and sarcomatosis of photodynamic therapy patients.

Authors:  Theresa M Busch; Stephen M Hahn; E Paul Wileyto; Cameron J Koch; Douglas L Fraker; Paul Zhang; Mary Putt; Kristen Gleason; Daniel B Shin; Michael J Emanuele; Kevin Jenkins; Eli Glatstein; Sydney M Evans
Journal:  Clin Cancer Res       Date:  2004-07-15       Impact factor: 12.531

9.  Calculation of singlet oxygen dose from photosensitizer fluorescence and photobleaching during mTHPC photodynamic therapy of MLL cells.

Authors:  Jonathan S Dysart; Gurmit Singh; Michael S Patterson
Journal:  Photochem Photobiol       Date:  2005 Jan-Feb       Impact factor: 3.421

10.  Singlet oxygen luminescence as an in vivo photodynamic therapy dose metric: validation in normal mouse skin with topical amino-levulinic acid.

Authors:  M J Niedre; C S Yu; M S Patterson; B C Wilson
Journal:  Br J Cancer       Date:  2005-01-31       Impact factor: 7.640

View more
  5 in total

1.  A Comparison of Dose Metrics to Predict Local Tumor Control for Photofrin-mediated Photodynamic Therapy.

Authors:  Haixia Qiu; Michele M Kim; Rozhin Penjweini; Jarod C Finlay; Theresa M Busch; Tianhao Wang; Wensheng Guo; Keith A Cengel; Charles B Simone; Eli Glatstein; Timothy C Zhu
Journal:  Photochem Photobiol       Date:  2017-02-22       Impact factor: 3.421

2.  Evaluation of singlet oxygen explicit dosimetry for predicting treatment outcomes of benzoporphyrin derivative monoacid ring A-mediated photodynamic therapy.

Authors:  Michele M Kim; Rozhin Penjweini; Timothy C Zhu
Journal:  J Biomed Opt       Date:  2017-02-01       Impact factor: 3.170

3.  PDT dose dosimetry for Photofrin-mediated pleural photodynamic therapy (pPDT).

Authors:  Yi Hong Ong; Michele M Kim; Jarod C Finlay; Andreea Dimofte; Sunil Singhal; Eli Glatstein; Keith A Cengel; Timothy C Zhu
Journal:  Phys Med Biol       Date:  2017-12-29       Impact factor: 3.609

4.  Validation of combined Monte Carlo and photokinetic simulations for the outcome correlation analysis of benzoporphyrin derivative-mediated photodynamic therapy on mice.

Authors:  Karl W Beeson; Evgueni Parilov; Mary Potasek; Michele M Kim; Timothy C Zhu
Journal:  J Biomed Opt       Date:  2019-03       Impact factor: 3.170

5.  Reactive oxygen species explicit dosimetry to predict tumor growth for benzoporphyrin derivative-mediated vascular photodynamic therapy.

Authors:  Tianqi Sheng; Yi Hong Ong; Wensheng Guo; Timothy Zhu
Journal:  J Biomed Opt       Date:  2020-01       Impact factor: 3.170

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.